We are live on ! Find out more

1,737 hedge funds and large institutions have $138B invested in Pfizer in 2013 Q4 according to their latest regulatory filings, with 210 funds opening new positions, 590 increasing their positions, 754 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more first-time investments, than exits

New positions opened: 210 | Existing positions closed: 62

8% more funds holding

Funds holding: 1,6061,737 (+131)

4% more capital invested

Capital invested by funds: $133B → $138B (+$4.97B)

4% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.23B

0.48% less ownership

Funds ownership: 73.66%73.18% (-0.48%)

2% less funds holding in top 10

Funds holding in top 10: 254250 (-4)

22% less repeat investments, than reductions

Existing positions increased: 590 | Existing positions reduced: 754

Holders
1,737
Holders Change
+131
Holders Change %
+8.16%
% of All Funds
50.39%
Holding in Top 10
250
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-1.57%
% of All Funds
7.25%
New
210
Increased
590
Reduced
754
Closed
62
Calls
$1.28B
Puts
$1.23B
Net Calls
+$44.3M
Net Calls Change
-$16M
Name Holding Trade Value Shares
Change
Change in
Stake
IC
26
Institutional Capital
Illinois
$1.22B -$5.97M -204,975 -0.5%
TCIM
27
TIAA CREF Investment Management
New York
$1.12B +$25.9M +890,284 +2%
Goldman Sachs
28
Goldman Sachs
New York
$1.11B +$16.8M +578,824 +2%
Legal & General Group
29
Legal & General Group
United Kingdom
$981M -$10.2M -349,473 -1%
Morgan Stanley
30
Morgan Stanley
New York
$945M +$8.18M +281,221 +0.9%
Fisher Asset Management
31
Fisher Asset Management
Washington
$932M -$8.32M -286,001 -0.9%
Boston Partners
32
Boston Partners
Massachusetts
$893M +$45.4M +1,558,569 +5%
Dimensional Fund Advisors
33
Dimensional Fund Advisors
Texas
$873M +$13.2M +454,260 +2%
LSV Asset Management
34
LSV Asset Management
Illinois
$854M +$18.5M +634,857 +2%
Neuberger Berman Group
35
Neuberger Berman Group
New York
$827M -$20.1M -692,171 -2%
Grantham, Mayo, Van Otterloo & Co (GMO)
36
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$821M -$642M -22,052,086 -44%
BIM
37
BlackRock Investment Management
Delaware
$797M -$12.8M -439,485 -2%
MAA
38
Managed Account Advisors
New Jersey
$775M -$22.6M -777,255 -3%
Lazard Asset Management
39
Lazard Asset Management
New York
$738M -$158M -5,443,513 -18%
Allianz Asset Management
40
Allianz Asset Management
Germany
$695M -$124M -4,270,454 -15%
Wells Fargo
41
Wells Fargo
California
$688M +$17M +585,718 +3%
UBS AM
42
UBS AM
Illinois
$685M +$923K +31,729 +0.1%
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$660M -$26.1M -897,762 -4%
American Century Companies
44
American Century Companies
Missouri
$659M -$12.7M -437,934 -2%
LP
45
Longview Partners
Guernsey
$647M +$82.9M +2,847,666 +15%
WRF
46
Waddell & Reed Financial
Kansas
$623M -$8.78M -301,711 -1%
California Public Employees Retirement System
47
California Public Employees Retirement System
California
$622M +$100M +3,437,577 +19%
Charles Schwab
48
Charles Schwab
California
$617M -$62.5M -2,147,986 -9%
PNC Financial Services Group
49
PNC Financial Services Group
Pennsylvania
$614M -$15.7M -540,964 -2%
BlackRock
50
BlackRock
New York
$582M +$46.6M +1,601,046 +9%

PFE Hedge Fund Activity: Q4 2013 in Review

1,737 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2013, worth a combined $138B — up 3.7% from $133B a quarter earlier.

Buyers outnumbered sellers: 210 funds opened new PFE positions and 62 closed out — a net gain of 148 holders — while 590 added to existing stakes and 754 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $230M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $642M.

  • 1,737 institutional investors held Pfizer (PFE) as of Q4 2013, up from 1,606 in Q3 2013.
  • Funds reported $138B of Pfizer stock for Q4 2013, up 3.7% quarter-over-quarter.
  • 210 funds opened new Pfizer positions in Q4 2013 and 62 closed out, a net change of +148 holders.
  • The largest Pfizer buyer in Q4 2013 was Renaissance Technologies, an estimated $230M added.
  • The largest Pfizer seller in Q4 2013 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $642M sold.

Based on aggregated 13F filings for Q4 2013.